KLK3 and Familial prostate cancer: Eight trials [11, 14, 18–21, 23, 25] showed a benefit of CHM for this outcome (at least 2.38 ug/l PSA lower in CHM group), and the remaining five trials [13, 17, 24, 26, 27] showed no difference between groups on controlling serum PSA in prostate cancer patients.